1. Rare Oral Presentation of a Mycophenolate Mofetil-Related Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder (MMF-OIA-LPD) Lesion: A Case Report and Literature Review
- Author
-
Cyrus M. Khan, Yazan Samhouri, Joseph E. Cillo, Andrew Taliaferro, and Jeremy Rice
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Lymphoproliferative disorders ,Immunosuppression ,030206 dentistry ,Disease ,medicine.disease ,Dermatology ,Scleroderma ,stomatognathic diseases ,03 medical and health sciences ,0302 clinical medicine ,Otorhinolaryngology ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Rheumatoid arthritis ,medicine ,Surgery ,Methotrexate ,Oral Surgery ,business ,Osteonecrosis of the jaw ,Immunodeficiency ,medicine.drug - Abstract
Oral manifestations of side effects of medications, such as methotrexate (MTX) for management of rheumatoid arthritis (RA) and mycophenolate mofetil (MMF) for solid organ transplant (SOT), are very rare. The known side effects include entities called other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD) due to immunosuppression caused by these medications. While there has been an increased incidence of oral cavity LPD reported in the literature associated with MTX, oral presentations that involve MMF are rare. This case report will detail a 74-year-old man with scleroderma treated with MMF who developed Epstein-Barr virus + polymorphic B-cell lymphoproliferative disorder in the right maxillary gingiva presenting as osteonecrosis of the jaw (ONJ). His oral presentation was successfully treated with a combination of surgery and MMF dosage reduction with an oral presentation free of disease at 6 months follow-up. This is the first known case report of an oral manifestation of MMF-related OIIA-LPD.
- Published
- 2021
- Full Text
- View/download PDF